読み込み中
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
前日終値
$6.05
+$0.04 · +0.67%
日中の時刻はETです。市場データは遅延する場合があります。
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
日中レンジ
現在 $6.05
52週レンジ
現在 $6.05
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
46
適正価値
センチメント
66
強気
リスク
75
高リスク
モメンタム
20
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
日中レンジ
現在 $6.05
52週レンジ
現在 $6.05
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2026年度 | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|---|
| 売上高 | — | — | — | 57.42万 USD | 29.42万 USD |
| 粗利益 | — | — | — | 57.42万 USD | 29.42万 USD |
| 研究開発 | 191.2万 USD | 221.2万 USD | 252万 USD | 274.5万 USD | 234.1万 USD |
| 販売・一般管理 | 729.36万 USD | 934.14万 USD | 1263.66万 USD | 1247.29万 USD | 1071.51万 USD |
| 営業費用 | 729.36万 USD | 934.14万 USD | 1263.66万 USD | 1247.29万 USD | 1071.51万 USD |
| 受取利息 | 15.65万 USD | 29.81万 USD | 42.84万 USD | 1.1万 USD | — |
| 支払利息 | 1.44万 USD | 1.01万 USD | — | — | — |
| 減価償却費と償却費 | 32.37万 USD | 33.96万 USD | 35.91万 USD | 24.09万 USD | 12.37万 USD |
| 営業利益 | −729.36万 USD | −934.14万 USD | −1263.66万 USD | −1189.86万 USD | −1042.09万 USD |
| 純利益 | −715.15万 USD | −1338.81万 USD | −1220.82万 USD | −1202.98万 USD | −1041.61万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
評価サンプルは3件と限定的です
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
